Filed (PHiled). Greater than 1-2 years since publication

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience

David Edward Youssef, Stephanie S. Handler, Susan Marjorie Richards, Catherine Anne Sheppard, Jenna Smith, Kathryn Tillman, Matthew Pietrosanu, Edward Kirkpatrick, Angela Bates University of Alberta and Stollery Children’s Hospital. Medical College of Wisconsin.Canada and United States Frontiers in PediatricsFront Pediatr 2023; DOI: 10.3389/fped.2023.1055131 AbstractIntroduction: Phosphodiesterase type 5 (PDE5) inhibitors, with sildenafil the earliest among them, are widely used […]

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience Read More »

Sleep disordered breathing and its relation to stroke and pulmonary hypertension in children with sickle cell disease: a single-center cross-sectional study

Azza Tantawy, Nayera El‑Sherif, Sara Makkeyah, Nahed Salah Eldeen, Noura Bahaa El‑Din Farghal, Nanies Soliman, Fatma S. E. EbeidAin Shams University.Egypt Annals of HematologyAnn Hematol 2023; 102: 271-281DOI: 10.1007/s00277-023-05099-4 AbstractSleep disordered breathing (SDB) is a common underdiagnosed sequela of sickle cell disease (SCD) that has been linked to the frequency of vaso-occlusive crises. To determine the frequency of SDB in children with SCD and its association to SCD-related

Sleep disordered breathing and its relation to stroke and pulmonary hypertension in children with sickle cell disease: a single-center cross-sectional study Read More »

Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension

Stefan Willmann, Andrea Kerstin Keller, Michaela Meyer, Dorina van der Mey, Gagriela Wirsching, Yang Zhang, Henk-Jan Drenth, Anne Keunecke, Esmée Vendel, Soundos SalehBayer AG. LAP&P Consultants.Germany Pediatric PulmonologyPediatr Pulmonol 2023; 58: 908-917DOI: 10.1002/ppul.26277 AbstractBackground: The PATENT-CHILD study investigated riociguat in children aged ≥ 6 to <18 years with pulmonary arterial hypertension (PAH) treated with tablets or an

Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension Read More »

Inhibition of the prolyl isomerase Pin1 improves endothelial function and attenuates vascular remodelling in pulmonary hypertension by inhibiting TGF-β signalling

Kondababu Kurakula, Quint A. J. Hagdorn, Diederik E. van der Feen, Anton Vonk Noordegraaf, Peter ten Dijke, Rudolf A. de Boer, Harm Jan Bogaard, Marie José Goumans, Rolf M. F. BergerLeiden University Medical Center. University of Groningen and Beatrix Children’s Hospital. Vrije Universiteit Amsterdam. University of Groningen and University Medical Center Groningen.Netherlands AngiogenesisAngiogenesis 2022; 25: 99-112DOI: 10.1007/s10456-021-09812-7 AbstractPulmonary arterial hypertension (PAH) is a devastating disease, characterized by obstructive pulmonary vascular remodelling ultimately leading to right ventricular (RV) failure

Inhibition of the prolyl isomerase Pin1 improves endothelial function and attenuates vascular remodelling in pulmonary hypertension by inhibiting TGF-β signalling Read More »

A North American, single-center experience implanting fenestrated atrial devices and atrial flow regulators into a heterogeneous group of pediatric pulmonary hypertension patients

David Edward Youssef, Konstantin Averin, Susan Richards, Catherine Sheppard, Cameron Seaman, Matthew Pietrosanu and Angela BatesUniversity of Alberta and Stollery Children’s Hospital. Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.Canada and United States Frontiers in PediatricsFront Pediatr 2023; 11: DOI: 10.3389/fped.2023.1073336 AbstractIntroduction: The clinical deterioration commonly experienced by pediatric patients with pulmonary arterial hypertension (PAH) has

A North American, single-center experience implanting fenestrated atrial devices and atrial flow regulators into a heterogeneous group of pediatric pulmonary hypertension patients Read More »

Quantifying side effects and caregiver burdens of pediatric pulmonary hypertension therapies

Erik J. Nelson, Ella Cook, Samara Nelson, Rebecca Brown, Megan Pierce, Ashley Bangerter Seelos, Heather Stickle and Michael JohansenBrigham Young University. Utah State University. Indiana University School of Medicine. United States BioMed Central PediatricsBMC Pediatr 2023; 23: DOI: 10.1186/s12887-023-03860-2 AbstractBackground and objectives: Pulmonary hypertension (PH) is a rare, but serious disease among children. However, PH has been

Quantifying side effects and caregiver burdens of pediatric pulmonary hypertension therapies Read More »

Pulmonary hypertension screening in children with sickle cell disease

Kok Hoe Chan, Syeda Hiba Rizvi, Wilfredo De Jesus-Rojas, James M. Stark, Ricardo A. Mosquera, Adrianna Carolina Prada-Ruiz, Traci Gonzalez, Deborah L. Brown, Neethu M. Menon, Trinh T. Nguyen, Cindy K. Jon, Aravind YadavUniversity of Texas Health Science Center at Houston. Ponce Health Science University and Ponce Research Institute. Baylor College of Medicine.United States Pediatric

Pulmonary hypertension screening in children with sickle cell disease Read More »

G9a/GLP Targeting Ameliorates Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension

Charifa Awada, Alice Bourgeois, Sara-Eve Lemay, Yann Grobs, Tetsuro Yokokawa, Sandra Breuils-Bonnet, Sandra Martineau, Vinod Krishna, Francois Potus, Jey Jevaseelan, Steeve ProvencherCentre de recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec. Janssen Research and Development. Canada American Journal of Respiratory Cell and Molecular BiologyAm J Respir Cell Mol Biol 2023; DOI: 10.1165/rcmb.2022-0300OC AbstractPulmonary

G9a/GLP Targeting Ameliorates Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension Read More »

Quantitative Assessment of Regional Pulmonary Transit Times in Pulmonary Hypertension

Jackson E, Moore, John W. Cerne, Ashitha Pathrose, Manik Veer, Roberto Sarnari, Ann Ragin, James C. Carr, Michael MarklNorthwestern UniversityUnited States Journal of Magnetic Resonance ImagingJ Magnet Reson Imag 2023; 57:727-737DOI: 10.1002/jmri.28343 AbstractBackground: Pulmonary hypertension (PH) contributes to restricted flow through the pulmonary circulation characterized by elevated mean pulmonary artery pressure acquired from invasive right heart catheterization

Quantitative Assessment of Regional Pulmonary Transit Times in Pulmonary Hypertension Read More »

BMPR2 Mutation and Metabolic Reprogramming in Pulmonary Arterial Hypertension

Iona Cuthbertson, Nicholas W. Morrel, Paola CarusoUniversity of Cambridge School of Clinical MedicineUnited Kingdom Circulation ResearchCirc Res 2023; 132(1):109-126DOI: 10.1161/CIRCRESAHA.122.321554 AbstractPulmonary arterial hypertension forms the first and most severe of the 5 categories of pulmonary hypertension. Disease pathogenesis is driven by progressive remodeling of peripheral pulmonary arteries, caused by the excessive proliferation of vascular wall cells,

BMPR2 Mutation and Metabolic Reprogramming in Pulmonary Arterial Hypertension Read More »

Scroll to Top